Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LDHB | P07195 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10094322 | 0.86 | KMO (0.56) | FFAR1LMNAKMT2AAKR1C3AKR1C2 | |
| SCHEMBL26356060 | 0.86 | AKR1C3 (0.47) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL10094517 | 0.82 | PARP1 (0.53) | BAZ2BBAZ2APARP1PDK2NPC1 | |
| SCHEMBL4067133 | 0.82 | CA12 (0.57) | PARP1CA12CA1CA2CA9 | |
| SCHEMBL23479668 | 0.82 | PDK2 (0.49) | PDK2FFAR1BRD4CREBBPLMNA | |
| SCHEMBL10094352 | 0.82 | KCNA5 (0.50) | BAZ2BBAZ2APDK2FFAR1BRD4 | |
| SCHEMBL23479756 | 0.82 | RAB9A (0.49) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL5307077 | 0.80 | PARP1 (0.56) | BAZ2BBAZ2APARP1PDK2NPC1 | |
| SCHEMBL4067125 | 0.79 | GABRA1 (0.45) | PARP1DHODHLMNAKMT2AAKR1C3 | |
| SCHEMBL30865718 | 0.79 | TRPA1 (0.51) | CA12CA1CA2CA9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049118-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | claimed |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 2021-06-10 | — | — | US | disclosed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, MPO | BAZ2B 1229/4885BAZ2A 1195/4885PARP1 2395/4885 |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, MPO | BAZ2B 1229/4885BAZ2A 1195/4885PARP1 2395/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | BAZ2B 1523/4885BAZ2A 1381/4885PARP1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.